November 14, 2014—Ten of the nation’s leading academic medical centers have asked Congress to investigate Genentech’s decision to move the world’s three top-selling cancer drugs into the more expensive specialty distribution channel.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)